Case Study: a large multinational biopharmaceutical company accelerates drug discovery with Capgemini AI

Integrating artificial intelligence (AI) into the drug discovery phase of pharmaceutical R&D

The customer, a large multinational biopharmaceutical company, faced immense pressure to reduce the high cost, time, and complexity of developing new drugs. To accelerate its R&D and leverage data science, the company turned to its strategic partner, Capgemini, to integrate artificial intelligence into its drug discovery processes.

Capgemini implemented AI and machine learning solutions, including applying neural networks from language translation to design new molecules and creating a unified system to simplify research workflows. This allowed the client's researchers to combine their scientific expertise with advanced AI. As a result, Capgemini helped the company increase the effectiveness of its drug discovery, remove inefficiencies, and accelerate innovation, transforming the entire process to be more intelligent and value-driven.